Among previously untreated patients, the ORR was higher—85% for NSCLC and 73% for RET-mutant medullary thyroid cancer (1-year PFS 92%)—while, for RET fusion-positive cancers other than NSCLC and thyroid cancer, the ORR was 43.9%. This evidence concerns the gene RET and cancer.